Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.
Monitoring therapeutic response to neoadjuvant chemotherapy(NAC) is likely to improve NAC effectiveness in breast cancer(BC). Imaging performance seems to vary per tumour subtype(by ER and HER2 status), therefore we performed a systematic review on subtype specific imaging performance in monitoring NAC in BC. Studies examining imaging performance in predicting pathologic complete response(pCR) during NAC in BC subtypes were selected. Per study, negative- and positive predictive value, sensitivity(se) and specificity(sp), AUC and accuracy were derived. Fifteen/106 articles were included. Inter-study variability was revealed in: monitoring interval, response and pCR definitions. In ER-positive/HER2-negative BC,181F FDG-PET/CT showed se/sp of 38%-89%/74%-100%, MRI showed se/sp of 35%-37%/87%-89%. In triple negative BC,181F FDG-PET/CT showed se/sp of 0%-79%/95%-100%.181F FDG-PET/CT showed in ER-positive/HER2-positive BC se/sp of 59%/80% and in ER-negative/HER2-positive 27%/88%. Evidence on imaging performance in monitoring NAC according BC subtypes is lacking. Consensus should be reached in: definitions of pCR, response and monitoring interval before starting well-designed studies.
Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Department of Health Technology and Services Research, MB-HTSR, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands. Electronic address: m.lindenberg@nki.nl.
Melanie A
MA
Lindenberg
Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Department of Health Technology and Services Research, MB-HTSR, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands. Electronic address: a.miquel@nki.nl.
Anna
A
Miquel-Cases
Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Department of Health Technology and Services Research, MB-HTSR, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands. Electronic address: v.retel@nki.nl.
Valesca P
VP
Retèl
Netherlands Cancer Institute, Medical Oncology Division, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: g.sonke@nki.nl.
Gabe S
GS
Sonke
Netherlands Cancer Institute, Diagnostic Oncology Division and Division of Molecular Pathology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: j.wesseling@nki.nl.
Jelle
J
Wesseling
Netherlands Cancer Institute, Division of Nuclear Medicine, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: m.stokkel@nki.nl.
Marcel P M
MPM
Stokkel
Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; Department of Health Technology and Services Research, MB-HTSR, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands. Electronic address: w.v.harten@nki.nl.
Wim H
WH
van Harten
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D003952:Diagnostic Imaging / Q000379:methods*; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Breast cancer; ER; HER2; Imaging; Neoadjuvant therapy; Therapeutic response